Welcome to our dedicated page for Siga Technologie SEC filings (Ticker: SIGA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SIGA Technologies, Inc. (SIGA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and related exhibits that together describe SIGA’s financial condition, business activities, and material events.
Recent Form 8-K filings by SIGA have reported the release of quarterly financial results, incorporating press releases that summarize product sales, total revenues, operating income or loss, and net income or loss for specific periods. These filings give context on the commercial performance of TPOXX (tecovirimat), including revenues from oral and IV formulations and the impact of deliveries to the U.S. Strategic National Stockpile and international customers.
Through its periodic reports, SIGA also discloses research and development revenues, cost of sales, selling, general and administrative expenses, and research and development expenses. The company’s filings discuss its contracts with U.S. government agencies such as BARDA, including development funding for pediatric programs and manufacturing support related to TPOXX, as well as broader risk factors tied to government contracts, regulatory approvals, intellectual property, and supply chain considerations.
On Stock Titan, these SEC filings are updated as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy documents, such as 10-K and 10-Q reports, by highlighting items like revenue composition, operating results, and significant contract or regulatory developments. Users can also review Form 8-K disclosures for material events, including earnings announcements and capital management decisions such as special cash dividends.
This page is a resource for investors and researchers who want to understand how SIGA describes its business, financial results, government relationships, and risk profile in its official SEC filings, with AI tools that make complex regulatory documents easier to interpret.
SIGA Technologies General Counsel Larry R. Miller reported routine equity compensation activity. On March 25, 2026, one-third of previously granted restricted stock units vested, resulting in the acquisition of 6,920 shares of common stock. To cover tax obligations, 3,526 shares were withheld by the company, leaving Miller with 51,912 common shares held directly after these transactions. The RSUs vest in three equal annual installments from the original March 25, 2024 grant date.
SIGA Technologies, Inc. declared a special, one-time cash dividend of $0.60 per share of its common stock. This dividend will be paid on April 23, 2026 to shareholders who are on record as of April 7, 2026. The announcement reflects a direct cash return to existing shareholders beyond any regular dividend activity.
SIGA Technologies Executive VP & CFO Daniel J. Luckshire reported routine equity compensation activity tied to restricted stock units (RSUs). On March 13, 2026, one-third of a prior RSU grant vested, resulting in 11,503 shares of Common Stock being issued at a conversion price of $0.00 per share.
To cover tax withholding obligations from the RSU vesting and share issuance, the company withheld 6,074 shares of Common Stock, valued at $5.26 per share based on the closing price on March 13, 2026. On the same date, Luckshire also received a new grant of 55,228 RSUs, which represent contingent rights to receive Common Stock on a one-for-one basis and vest over three years, one-third on each of the first three anniversaries of the grant date.
Following these transactions, Luckshire directly owns 280,493 shares of SIGA Technologies Common Stock and holds 55,228 RSUs. The filing reflects compensation-related vesting, a new RSU award, and tax withholding, rather than open-market buying or selling.
SIGA Technologies EVP and Chief Scientific Officer Dennis E. Hruby reported routine equity compensation activity. On March 13, 2026, one-third of a prior restricted stock unit (RSU) grant vested, converting 11,445 RSUs into the same number of common shares, while 3,955 shares were withheld at $5.26 per share to cover taxes. Following these transactions, he held 198,537 common shares directly. He also received a new award of 54,942 RSUs, which vest in three equal annual installments.
SIGA Technologies General Counsel Larry R. Miller reported routine equity compensation activity. On March 13, 2026, 21,261 restricted stock units vested and were settled into the same number of common shares. To cover associated tax obligations, the company withheld 11,187 shares at $5.26 per share. Miller also received a new grant of 68,060 restricted stock units, which vest in three equal annual installments from the grant date. Following these transactions, he directly holds 48,518 shares of common stock and has 68,060 restricted stock units outstanding.
SIGA Technologies Chief Executive Officer Diem Nguyen reported equity compensation activity involving restricted stock units (RSUs) and common shares on March 13, 2026. Nguyen exercised RSUs into 85,045 shares of common stock upon vesting of one-third of RSUs originally granted on March 13, 2025.
As part of this vesting, 47,029 shares of common stock were withheld by the company at $5.26 per share to cover tax obligations, rather than being sold in the market. In a separate transaction the same day, Nguyen received a new grant of 272,243 RSUs, each representing a contingent right to one share of common stock that vests over three years in equal annual installments.
Following these transactions, Nguyen directly owned 138,767 shares of common stock and held 272,243 RSUs, reflecting routine compensation-related equity awards and associated tax withholding.
SIGA Technologies describes its biodefense-focused pharmaceutical business built around TPOXX, an antiviral for smallpox and related orthopox viruses, sold mainly to governments. The company’s core U.S. revenue base is a BARDA contract contemplating up to approximately $630 million of payments for oral and IV TPOXX, pediatric and post‑marketing work.
SIGA also reports sales to the U.S. Department of Defense of about $10 million in 2024 and international oral TPOXX revenue of $5.8 million in 2025, versus $23.0 million in 2024. Future growth depends heavily on new U.S. stockpiling contracts and recurring non‑U.S. government demand.
The filing highlights regulatory risk: European and U.K. approvals for Tecovirimat‑SIGA were granted under “exceptional circumstances” and are undergoing annual reassessment after mpox trials (PALM007, STOMP, UNITY) failed to show statistically significant efficacy on primary endpoints. The CHMP is expected to decide in March whether to maintain, modify, suspend, or withdraw indications, which could reduce mpox‑related revenue. SIGA notes a broad global patent estate on TPOXX with key protections extending into the 2030s and an employee base of 49 as of February 13, 2026.
SIGA Technologies reported sharply lower results for 2025 but remained profitable. Total revenues were $94.6 million, down from $138.7 million in 2024, as product sales declined to $88.0 million from $133.3 million. Net income fell to $23.3 million, with diluted earnings per share of $0.32 versus $0.82 a year earlier.
Management highlighted $27 million of additional U.S. government funding secured in 2025 to support development and a $13 million oral TPOXX procurement order from an Asia Pacific customer received in January 2026. The balance sheet showed $154.9 million in cash and cash equivalents as of December 31, 2025 and total stockholders’ equity of $198.8 million.
SIGA Technologies Chief Executive Officer Diem Nguyen reported equity compensation activity involving restricted stock units and common shares. On January 27, 2026, 55,902 restricted stock units vested and converted into the same number of common shares at an exercise price of $0 per share.
To cover tax withholding related to this vesting, the issuer withheld 22,804 common shares at $6.82 per share, reducing Nguyen’s directly held common shares to 100,751. Following these transactions, Nguyen also held 55,903 restricted stock units, which continue to vest in equal annual installments over three years from the January 27, 2024 grant date.
SIGA Technologies (SIGA) reported Q3 2025 results showing lower quarterly activity amid timing of product deliveries. Revenue was $2.62 million, down from $10.01 million a year ago, with no point‑in‑time product delivery recognized in the quarter and $1.73 million from research and development services.
The quarter posted a net loss of $6.37 million versus net income of $1.34 million last year, reflecting higher self‑funded R&D and lower sales. Year to date, performance remains strong: nine‑month revenue was $90.78 million (vs. $57.25 million) and net income was $28.71 million (vs. $13.45 million). Cash and cash equivalents were $171.96 million as of September 30, 2025, after paying a $0.60 per share special dividend on May 15, 2025.
Under the 19C BARDA Contract, the company cites up to approximately $630 million of contemplated payments, with $79.1 million of 2025 revenue recognized at a point in time through September 30. The EMA initiated a referral to review Tecovirimat‑SIGA following mixed mpox trial readouts; approvals in other markets remain as stated. As of October 24, 2025, 71,611,302 shares were outstanding.